Fig. 8From: First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysisThe cost-effectiveness acceptability curves of all randomized patients. CE Cost-effectiveness, A All randomized patients, NI Nivolumab plus ipilimumab, C Pemetrexed plus cisplatin/carboplatinBack to article page